Strategic takeover deal ahead of the holidays French pharmaceutical giant Sanofi has reached an agreement to acquire Dynavax, a California-based... Read more
Tag: #M&A
AstraZeneca Inks $2 Billion Deal to Secure Next-Generation Cancer Inhibition Technology
AstraZeneca has officially entered into a global licensing agreement worth up to $2 billion for Jacobio Pharma’s Pan-KRAS inhibitor candidate,... Read more
Rare Disease Market Shifts as Shionogi Inks $2.5 Billion Asset Acquisition
On December 22, Shionogi revealed a definitive agreement to acquire the amyotrophic lateral sclerosis (ALS) portfolio from Tanabe Pharma. The... Read more
Biomarin executes record-breaking $4.8 billion acquisition of amicus therapeutics
Biopharmaceutical giant BioMarin has announced an agreement to acquire Amicus Therapeutics for $4.8 billion. This transaction represents the largest in... Read more
Biopharma Firm Finalizes Takeover of French Immuno-Oncology Specialist
The international biopharmaceutical corporation, Ipsen, successfully concluded its purchase of ImCheck Therapeutics on December 15, 2025, in Paris, France. This... Read more
Pharmaceutical Manufacturer Gaelic Labs Acquires Athlone Laboratories
Gaelic Laboratories, a pharmaceutical manufacturer specializing in Beta-Lactam (penicillin) products, has acquired Athlone Laboratories, a developer and manufacturer of oral... Read more
Major Biotech Deal: Sobi Acquires Arthrosi in Transaction Valued Up to $1.5 Billion
On December 15, 2025, Swedish Orphan Biovitrum AB (Sobi), a global biopharma company based in Stockholm, announced that it has... Read more
Mirum Pharmaceuticals Expands Portfolio With Bluejay Therapeutics Acquisition
Transaction Overview and Terms Mirum Pharmaceuticals Inc., a specialty pharmaceutical company focused on rare diseases, has reached an agreement to... Read more
Viatris Exits Preferred Equity Stake in Biocon Biologics in Major Transaction
The global healthcare enterprise Viatris has executed definitive agreements for the divestiture of its entire convertible preferred equity holding in... Read more









